USA: Zymeworks acquisisce Theravance Biopharma, focus su YUPELRI per diversificare il portafoglio e accelerare la crescita – Padovanews
Zymeworks Inc. agreed to acquire Theravance Biopharma, adding YUPELRI (revefenacin) for COPD. The deal values Theravance at $17/share, with a $350 million non-recourse note and $219 million cash plus Theravance’s estimated $360 million net cash at closing. YUPELRI U.S. net sales were $266.6M in 2025. Expected close in H2 2026.
How this was made
The 30-second read
Why it matters
The acquisition is a definitive M&A event with disclosed valuation, cash contribution, and product revenue/milestone context, enabling traders to model deal-spread risk, approval probability, and post-close revenue durability.
Market read
Definitive deal terms, product revenue figures, and expected closing window create a clear catalyst for M&A pricing and risk management.
What to watch
Deal certainty hinges on regulatory approvals and customary closing conditions; additionally, the $350m non-recourse note is secured by U.S. profit shares, which could affect downside protection assumptions in deal-spread trading.
Background
Zymeworks is pursuing a strategy of creating royalty-like economics via acquisitions and restructuring, and this deal is positioned as a strategic priority from earlier in the year.
Ticker impact
Zymeworks signed a definitive deal to acquire Theravance, adding YUPELRI and expanding/diversifying its partnered revenue base.
Likely positive bias into deal-close expectations, with volatility around regulatory approval and financing/cash deployment details.
The article discloses definitive M&A economics (price per share, cash contribution, note structure) and product revenue figures, which are actionable for deal-spread and risk assessment.
Market effects
Adds a long-acting COPD inhalation asset (YUPELRI) to a royalty-like acquisition model, reinforcing consolidation/portfolio diversification in respiratory pharma.
Irish tax attributes and U.S. profit-share note structure highlight cross-border structuring, but the commercial revenue is U.S.-centric per the article.
YUPELRI royalties/milestones outside the U.S. and generic launch timing (April 2039) matter for global COPD competitive dynamics.
Counterpoint
The article flags a near-term impact on commercial royalty revenue for Zymeworks, so the market may discount the deal if integration and royalty economics disappoint.
Key entities
- companyZymeworks Inc.
Acquirer signing a definitive agreement to buy Theravance Biopharma and add YUPELRI to its portfolio.
- companyTheravance Biopharma, Inc.
Target company valued at $17 per share in the definitive acquisition agreement.
- productYUPELRI (revefenacin)
Long-acting nebulized LAMA for maintenance treatment of chronic obstructive pulmonary disease (COPD).
- investorOMERS Life Sciences
Subscribes to the $350 million non-recourse note secured by U.S. profit shares from YUPELRI.
